MX338130B - Compuestos de benzazepina. - Google Patents
Compuestos de benzazepina.Info
- Publication number
- MX338130B MX338130B MX2012010570A MX2012010570A MX338130B MX 338130 B MX338130 B MX 338130B MX 2012010570 A MX2012010570 A MX 2012010570A MX 2012010570 A MX2012010570 A MX 2012010570A MX 338130 B MX338130 B MX 338130B
- Authority
- MX
- Mexico
- Prior art keywords
- urinary incontinence
- ht2c receptor
- obesity
- urge
- receptor agonist
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se describe un compuesto que es útil como un agente terapéutico o profiláctico para enfermedades asociadas con el receptor 5-HT2C, especialmente para incontinencia urinaria, tal como incontinencia urinaria de esfuerzo, incontinencia urinaria de urgencia e incontinencia urinaria mixta, disfunción sexual, tal como disfunción eréctil, obesidad y similares. Se han realizado estudios con respecto a los compuestos que tienen una acción agonista del receptor 5-HT2C y son así prometedores como ingredientes activos de composiciones farmacéuticas para el tratamiento o profilaxis de incontinencia urinaria, tal como incontinencia urinaria por estrés, incontinencia urinaria de urgencia e incontinencia urinaria mixta, disfunción sexual tal como disfunción eréctil, obesidad y similares, y se confirma que un compuesto de benzazepina específico tiene una excelente acción agonista del receptor 5-HT2C. El compuesto de benzazepina tiene una acción agonista del receptor 5-HT2C y puede utilizarse como un agente terapéutico o profiláctico para enfermedades asociadas con el receptor 5-HT2C, especialmente para incontinencia urinaria, tal como incontinencia urinaria por estrés, incontinencia urinaria de urgencia e incontinencia urinaria mixta, disfunción sexual tal como disfunción eréctil, obesidad y similares.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31313310P | 2010-03-12 | 2010-03-12 | |
| PCT/JP2011/055759 WO2011111817A1 (ja) | 2010-03-12 | 2011-03-11 | ベンゾアゼピン化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012010570A MX2012010570A (es) | 2012-11-23 |
| MX338130B true MX338130B (es) | 2016-04-04 |
Family
ID=44563615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012010570A MX338130B (es) | 2010-03-12 | 2011-03-11 | Compuestos de benzazepina. |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US20110269744A1 (es) |
| EP (1) | EP2546255B1 (es) |
| JP (1) | JP5747910B2 (es) |
| KR (1) | KR101769642B1 (es) |
| CN (1) | CN102869665B (es) |
| AU (1) | AU2011225108C1 (es) |
| BR (1) | BR112012022915B1 (es) |
| CA (1) | CA2792918C (es) |
| CY (1) | CY1118268T1 (es) |
| DK (1) | DK2546255T3 (es) |
| EA (1) | EA023039B1 (es) |
| ES (1) | ES2605466T3 (es) |
| HR (1) | HRP20161529T1 (es) |
| HU (1) | HUE031082T2 (es) |
| IL (1) | IL221737A (es) |
| LT (1) | LT2546255T (es) |
| MX (1) | MX338130B (es) |
| PL (1) | PL2546255T3 (es) |
| PT (1) | PT2546255T (es) |
| RS (1) | RS55362B1 (es) |
| SI (1) | SI2546255T1 (es) |
| TW (1) | TWI495640B (es) |
| UA (1) | UA110479C2 (es) |
| WO (1) | WO2011111817A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| GB2520266A (en) * | 2013-11-13 | 2015-05-20 | Ibm | Cursor-Based Character input interface |
| JP6556225B2 (ja) * | 2014-09-17 | 2019-08-07 | セルジーン シーエーアール エルエルシー | Ｍｋ２阻害剤およびその使用 |
| US10452679B2 (en) * | 2016-09-30 | 2019-10-22 | Google Llc | Systems and methods for context-sensitive data annotation and annotation visualization |
| US20210052600A1 (en) * | 2017-12-27 | 2021-02-25 | Takeda Pharmaceutical Company Limited | Therapeutic agents for stress urinary incontinence and incotinence of feces |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2002074746A1 (ja) * | 2001-03-16 | 2004-07-08 | 山之内製薬株式会社 | ベンゾアゼピン誘導体 |
| US6953787B2 (en) | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
| WO2005003096A1 (en) | 2003-06-17 | 2005-01-13 | Arena Pharmaceuticals, Inc. | Benzazepine derivatives useful for the treatment of 5ht2c receptor associated diseases |
| US20080009478A1 (en) | 2003-10-22 | 2008-01-10 | Arena Pharmaceuticals, Inc. | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases |
| US20070275949A1 (en) | 2003-10-22 | 2007-11-29 | Arena Pharmaceuticals, Inc. | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2C Receptor Associated Diseases |
| US8022062B2 (en) * | 2004-02-25 | 2011-09-20 | Eli Lilly And Company | 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists |
| GB0412314D0 (en) | 2004-06-02 | 2004-07-07 | Glaxo Group Ltd | Compounds |
| TW201031661A (en) | 2009-02-17 | 2010-09-01 | Targacept Inc | Fused benzazepines as neuronal nicotinic acetylcholine receptor ligands |
-
2011
- 2011-03-09 US US13/044,080 patent/US20110269744A1/en not_active Abandoned
- 2011-03-11 SI SI201131007A patent/SI2546255T1/sl unknown
- 2011-03-11 US US13/583,410 patent/US20130012496A1/en not_active Abandoned
- 2011-03-11 ES ES11753475.0T patent/ES2605466T3/es active Active
- 2011-03-11 PT PT117534750T patent/PT2546255T/pt unknown
- 2011-03-11 BR BR112012022915-0A patent/BR112012022915B1/pt active IP Right Grant
- 2011-03-11 LT LTEP11753475.0T patent/LT2546255T/lt unknown
- 2011-03-11 PL PL11753475T patent/PL2546255T3/pl unknown
- 2011-03-11 EA EA201290905A patent/EA023039B1/ru not_active IP Right Cessation
- 2011-03-11 CN CN201180013703.2A patent/CN102869665B/zh active Active
- 2011-03-11 CA CA2792918A patent/CA2792918C/en active Active
- 2011-03-11 EP EP11753475.0A patent/EP2546255B1/en active Active
- 2011-03-11 AU AU2011225108A patent/AU2011225108C1/en not_active Ceased
- 2011-03-11 MX MX2012010570A patent/MX338130B/es active IP Right Grant
- 2011-03-11 WO PCT/JP2011/055759 patent/WO2011111817A1/ja active Application Filing
- 2011-03-11 KR KR1020127026576A patent/KR101769642B1/ko active IP Right Grant
- 2011-03-11 HU HUE11753475A patent/HUE031082T2/en unknown
- 2011-03-11 RS RS20161038A patent/RS55362B1/sr unknown
- 2011-03-11 JP JP2012504533A patent/JP5747910B2/ja not_active Expired - Fee Related
- 2011-03-11 DK DK11753475.0T patent/DK2546255T3/en active
- 2011-03-11 TW TW100108310A patent/TWI495640B/zh not_active IP Right Cessation
- 2011-11-03 UA UAA201211777A patent/UA110479C2/uk unknown
-
2012
- 2012-09-02 IL IL221737A patent/IL221737A/en not_active IP Right Cessation
- 2012-09-13 US US13/613,948 patent/US9108977B2/en active Active
-
2015
- 2015-07-13 US US14/797,277 patent/US9598434B2/en active Active
-
2016
- 2016-11-21 HR HRP20161529TT patent/HRP20161529T1/hr unknown
- 2016-11-29 CY CY20161101235T patent/CY1118268T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA106634C2 (uk) | Тверда фармацевтична дозована форма | |
| MX2011011178A (es) | Compuesto de diaciletilendiamina. | |
| MX2022009942A (es) | Composiciones farmaceuticas que comprenden epa y un agente cardiovascular y metodos para utilizar el mismo. | |
| WO2008028076A3 (en) | Therapeutic devices for the treatment of various conditions of a female individual | |
| AU2012253757A8 (en) | Partially saturated tricyclic compounds and methods of making and using same | |
| NZ610034A (en) | Prevention of adverse effects caused by cd3 specific binding domains | |
| MX2011011950A (es) | Composiciones de dexmedetomidina sublinguales y metodos de uso de las mismas. | |
| MX2013006911A (es) | Peliculas sub-linguales. | |
| CY1118268T1 (el) | Ενωση βενζαζεπινης | |
| UA105911C2 (uk) | Сульфонамідні похідні | |
| MX2009009153A (es) | Pirano-pirazol-aminas. | |
| MX2011008171A (es) | Composicion farmaceutica que comprende linagliptina y opcionalmente un inhibidor de sglt2, y usos de la misma. | |
| WO2009056550A3 (en) | Bupropion hydrobromide and therapeutic applications | |
| MX2009004745A (es) | Derivados de 1,2,3-triazol como inhibidores del receptor sigma. | |
| GB201104241D0 (en) | Dosages for menstrual suppression, contraception, and hormone replacement therapy, and methods of administrating same | |
| MX2010001449A (es) | Bromhidrato de bupropion y aplicaciones terapeuticas. | |
| WO2011048553A3 (en) | Pharmaceutical compositions of pde-5 inhibitors and dapoxetine | |
| MX347237B (es) | Formulaciones farmaceuticas y usos de las mismas en el tratamiento de la disfuncion sexual femenina. | |
| MX2011009033A (es) | Inhibidores triciclicos de cinasa pirazolopiridina. | |
| IN2012DN01434A (es) | ||
| MX2009009154A (es) | Derivados de espiro-pirano-pirazol. | |
| EP2438923A4 (en) | COMPOSITION FOR THE PREVENTION OR TREATMENT OF OBESITY-RELATED DISORDERS MEDIATED BY AMPK ACTIVATION AND THE ACTIVE INGREDIENTS OF WHICH HAVE 2,5-BIS-ARYL-3,4-DIMETHYLTETRAHYDROFURAN LIGNANS | |
| MX2014000066A (es) | Formulaciones mucoadhesivas en gel de alta dosificación de metronidazol de base acuosa y su uso para tratar la vaginosis bacteriana. | |
| WO2012050641A3 (en) | Use of trpa1 antagonists to prevent or treat infections caused by biological-warfare agents | |
| WO2014152451A3 (en) | Compositions and methods for controlled localized delivery of bone forming therapeutic agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |